Trial Profile
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Tagraxofusp (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Jun 2022 Planned End Date changed from 31 May 2024 to 31 May 2026.
- 13 Jun 2022 Planned primary completion date changed from 31 May 2022 to 31 May 2024.